Scotiabank raised the firm’s price target on Alnylam (ALNY) to $310 from $305 and keeps an Outperform rating on the shares. The company executed well in Q3, with Amvuttra showing strong demand growth across global geographies, the analyst tells investors. While lower-than-expected Onpattro sales and collaboration/royalty revenue drove misses on total revenue and EPS, the firm remains encouraged on fundamentals with reiteration of 2024 sales and opex guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $384 from $366 at Canaccord
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
- Alnylam price target raised to $329 from $295 at Barclays
- Alnylam Pharmaceuticals Reports Mixed Quarterly Earnings
- Alnylam sees FY24 combined net product revenues $1.58B – $1.65B
Questions or Comments about the article? Write to editor@tipranks.com